☆ 4.6 Article

A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*

CRITICAL CARE MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pathology

Immunopathology of Hyperinflammation in COVID-19

Joshua N. Gustine et al.

Summary: The rapid spread of COVID-19 has led to an unprecedented global public health crisis with recent studies suggesting that the hyperinflammatory syndrome induced by SARS-CoV-2 is a contributing factor to disease severity and mortality. Pathophysiological research shows that the hyperinflammatory syndrome in severe COVID-19 results from a dysregulated innate immune response. Current potential therapeutic approaches are being investigated to modulate the immune response and mitigate lung injury in severe COVID-19.

AMERICAN JOURNAL OF PATHOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2

Russell M. Petrak et al.

Summary: Tocilizumab, as an IL-6 receptor antagonist, has shown effectiveness in suppressing the cytokine storm in critically ill patients with SARS-CoV-2 infection, leading to reduced mortality. Early administration of the drug is associated with avoidance of mechanical ventilation and increased survival rates in patients.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial

Carlo Salvarani et al.

Summary: This study evaluated the use of tocilizumab in hospitalized COVID-19 pneumonia patients and found no significant benefit compared to standard care. Further randomized clinical trials with blinded, placebo-controlled methods are needed to confirm these results and explore potential applications of tocilizumab in different stages of the disease.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Viviane C. Veiga et al.

Summary: The study found that in patients with severe or critical COVID-19, tocilizumab in combination with standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open- label, multicentre, randomised, controlled, phase 3 trial

Arvinder S. Soin et al.

Summary: The study recruited 180 patients and found that tocilizumab did not reduce disease progression in patients with moderate to severe COVID-19, but may have some effect in severe cases.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹

Review Critical Care Medicine

Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials

Timothy Arthur Chandos Snow et al.

Summary: For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required. Its benefits may also lie in reducing the need for mechanical ventilation.

INTENSIVE CARE MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Alive and Ventilator Free: A Hierarchical, Composite Outcome for Clinical Trials in the Acute Respiratory Distress Syndrome*

Victor Novack et al.

CRITICAL CARE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Critical Care Medicine

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes

Christina C. Price et al.

CHEST (2020)

添加到收藏夹

Article Rheumatology

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Emanuel Della-Torre et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Bette Korber et al.

CELL (2020)

添加到收藏夹

Article Cell Biology

Efficacy and safety of tocilizumab in COVID-19 patients

Kai-Lian Zheng et al.

AGING-US (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Infectious Diseases

Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness

Manuel Rubio-Rivas et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Francesco Perrone et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Multidisciplinary Sciences

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review

Avi Gurion Kaye et al.

PEERJ (2020)

添加到收藏夹

Article Rheumatology

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Giovanni Guaraldi et al.

LANCET RHEUMATOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial

Farsad Eskandary et al.

TRIALS (2019)

添加到收藏夹

Editorial Material Medicine, General & Internal

Bayesian Analysis: Using Prior Information to Interpret the Results of Clinical Trials

Melanie Quintana et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Article Rheumatology

The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Michael E. Weinblatt et al.

ARTHRITIS & RHEUMATOLOGY (2015)

添加到收藏夹

Article Immunology

Soluble interleukin-6 receptor is elevated during influenza A virus infection and mediates the IL-6 and IL-32 inflammatory cytokine burst

Jun Wang et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2015)

添加到收藏夹

Article Mathematical & Computational Biology

A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information

Nigel Stallard

STATISTICS IN MEDICINE (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.